Physician profile
Kathryn E Mccarthy
NPI 1700850781
$2,570.88
in general payments reported to CMS, 2019-2025
23 companies · $685 in 2025
The $685 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $236 · 2022: $910 · 2023: $296 · 2024: $444 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $435.37 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $251.09 | 2025 | Lokelma, Airsupra |
| Teva Pharmaceuticals USA, INC. | $229.85 | 2024-2025 | Austedo Xr, Austedo Xr |
| Viiv Healthcare Company | $165.78 | 2024-2025 | Apretude, Dovato |
| Alnylam Pharmaceuticals INC. | $131.32 | 2024 | Onpattro |
| Otsuka America Pharmaceutical, INC. | $124.99 | 2023 | Rexulti |
| Novo Nordisk INC | $121.11 | 2022 | |
| Astellas Pharma US INC | $120.43 | 2024 | Veozah |
| Shield Therapeutics INC | $117.38 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $116.02 | 2023 | Dupixent |
| Horizon Therapeutics Plc | $114.66 | 2022 | |
| Phathom Pharmaceuticals, INC. | $110.57 | 2025 | Voquezna |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $99.99 | 2022 | |
| Sanofi Pasteur INC. | $98.68 | 2022 | |
| Sage Therapeutics, LLC | $97.15 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $76.20 | 2022 | |
| Coopersurgical, INC. | $33.90 | 2021 | |
| Sumitomo Pharma America, INC. | $23.60 | 2023 | Myfembree |
| Abiomed | $22.27 | 2024 | Impella |
| Hologic Sales and Service, LLC | $21.40 | 2022 | |
| Mayne Pharma Commercial LLC | $21.34 | 2022 | |
| Aspira Women'S Health INC | $21.20 | 2022 | |
| Myovant Sciences INC. | $16.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.